N/A N=39 Health Services Research

Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity

Breast Cancer

Bottom Line

View on ClinicalTrials.gov: NCT05871125 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2026

Primary outcome: Primary: Number of Patients Who Receive All Reimbursements and Who Complete Follow-up Surveys (Overall Feasibility of Intervention) — 33; 0 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Reimbursement (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: Female
Sponsor: University of Alabama at Birmingham
Primary completion: Dec 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients Who Receive All Reimbursements and Who Complete Follow-up Surveys (Overall Feasibility of Intervention)	33; 0	—

Summary

The goal of this clinical trial is to explore the feasibility and preliminary impact of a pilot financial reimbursement intervention for women with breast cancer living in the Deep South who are eligible for a clinical trial. The main questions it aims to answer are: 1. Can we recruit and retain patients on a clinical trial to a reimbursement study? 2. What is the preliminary impact of participation in a reimbursement study on patient financial hardship? Participants will receive a monthly reimbursement to compensate for their trial-incurred expenses. Researchers will use surveys and interviews to explore the impact of receiving reimbursement on trial-related outcomes and financial hardship for participating patients.

Eligibility Criteria

Inclusion Criteria

Participants will be women with breast cancer currently enrolled in the Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and Molecular AnaLysis (I-SPY TRIAL 2) at the UAB Medical Oncology Clinic.

Exclusion Criteria

Non-English speakers
Males
Females without cancer
Female cancer patients not enrolled in the I-SPY TRIAL 2

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05871125). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.